

## SHITED STATE. JEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
08/776,578	02/03/97	HARREUS	A	R45073

12M1/0515
OBLON SPIVAK MCCLELLAND AND MAIER
1755 JEFFERSON DAVIS HIGHWAY
FOURTH FLOOR
ARLINGTON VA 22202

EXAMINER

O SULLIVAN, P

ART UNIT PAPER NUMBER

1209

DATE MAILED: 05/15/97

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

Application No.

08/776,578

Applicant(s)

Examiner

Office Action Summary

Peter G. O'Sullivan

Group Art Unit 1209

Harreus et al.

Responsive to communication(s) filed on					
☐ This action is <b>FINAL</b> .					
☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
A shortened statutory period for response to this action is set to exist longer, from the mailing date of this communication. Failure to reapplication to become abandoned. (35 U.S.C. § 133). Extensions (37 CFR 1.136(a).	spond within the period for response will cause the				
Disposition of Claims					
	is/are pending in the application.				
Of the above, claim(s)	is/are withdrawn from consideration.				
☐ Claim(s)					
X Claim(s) 11-17					
☐ Claim(s)					
☐ Claims					
Application Papers  See the attached Notice of Draftsperson's Patent Drawing Record The drawing(s) filed on	to by the Examiner.  is approved disapproved.  er 35 U.S.C. § 119(a)-(d). e priority documents have been  )  rnational Bureau (PCT Rule 17.2(a)).				
<ul> <li>Acknowledgement is made of a claim for domestic priority under the content of the</li></ul>					
SEE OFFICE ACTION ON THE F	FOLLOWING PAGES				

Serial Number: 08/776,578

Art Unit:

- Claims 11-17 are pending in this application which should be reviewed for errors. 1. Claims 1-10 have been cancelled by applicants. Applicants are requested to sent a copy of the ACS Symposium Ser. mentioned as the D3 reference in the parent PCT application and on page 2 of applicants' specification.
- Claim11 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing 2. to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- Claim 17 recites the limitation "without a solvent" in line 2. There is insufficient 3. antecedent basis for this limitation in claim 1. It is recommended applicants include the term, "comprising" in claim 1 to allow for this further limitation.
- The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness 4. rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was

Page 3

Serial Number: 08/776,578

Art Unit:

made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

- Claims 11-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over the teaching 5. of the American Chemical Society (ACS Symposium Series 443, 1991, Chapter 18, pages 226-235) in view of Hong et al. The American Chemical Society reference discloses reacting acetone oxime and ethylene carbonate in toluene in the presence of potassium fluoride or tetramethylammonium chloride to yield the corresponding oximeglycol. The instant invention differs in that additional oximes and carbonates may be used, in that additional catalysts may be used and in that the reaction may be conducted in the absence of a solvent. Regarding the use of further reactants, the use of different, but analogous reactants in an old process does not render the process unobvious. In re Durden et al. 226 U.S.P.Q. 359. The use of applicants' specific catalysts is held to be obvious in view of the fact that the use of potassium salts and basic organic nitrogen compounds are already used as catalysts in the primary reference. Hong et al. discloses that a similar reaction may be conducted in the absence of a solvent. It would have been prima facie obvious at the time the invention was made to one of ordinary skill in the art to start with the teaching of the cited references, to make applicants' processes and to expect to make O-(2hydroxyalkyl)oximes.
- The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

Serial Number: 08/776,578

Art Unit:

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

- Claims 11-13 are rejected under 35 U.S.C. 102(b) as being anticipated by the American 7. Chemical Society (ACS Symposium Series 443, 1991, Chapter 18, pages 226-235). The American Chemical Society reference discloses reacting acetone oxime and ethylene carbonate in toluene in the presence of potassium fluoride or tetramethylammonium chloride to yield the corresponding oximeglycol.
- No claim is allowed in the absence of a clear deliniation of appicants' claims from prior art 8. processes and a showing of unexpected beneficial results in a comparison with the closest prior art. Applicants are encouraged to place limitation in their generic claims to distinguish their claims from the prior art processes and which may serve as a basis for comparison in any showing.
- Any inquiry concerning this communication should be directed to Peter O'Sullivan at 9. telephone number (703) 308-4526.